Literature DB >> 7768635

Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.

A J McAdam1, B A Pulaski, S S Harkins, E K Hutter, E M Lord, J G Frelinger.   

Abstract

While the effect of cytokines on the generation of tumor-reactive cytotoxic cells has been a topic of active investigation, the effect of physiological cytokine combinations has not been determined. We have investigated the effect of co-expression of IL-2 and IFN-gamma on the generation of cytotoxic cells against the murine line 1 tumor in vivo. These cytokines were selected because they are normally produced in concert by a subset of T-helper cells called T-helper 1 (Th1). We transfected the line 1 murine carcinoma with cDNA for IL-2 and IFN-gamma, alone or combined. IFN-gamma alone does not elicit rejection of the transfectant, but IL-2 increases the tumorigenic dose by 10,000-fold above the parental cells. Co-expression of IFN-gamma and IL-2 increases this rejection to at least 100,000-fold above parental line 1. Unlike IL-2 transfectants, tumor cells expressing both IFN-gamma and IL-2 can also elicit rejection of admixed parental tumor cells. Finally, the IFN-gamma/IL-2 transfectants are more effective at generating memory cells that are cytolytic for the parental tumor. Our results show that synergistic interactions of Th1 cytokines can remarkably enhance the cytotoxic response to tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768635     DOI: 10.1002/ijc.2910610508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Early effects of low dose C ion or x-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer.

Authors:  Yingtai Chen; Xuezhong Chen; Yumin Li; Hong Zhang; Yi Xie; Xiaowei Zhang; Huizi Ren; Yanling Wang; Shiqi Liao; Mingyan He; Jinyu Ren; Jieyu Zhang; Xiadong Zhou; Tongzhang Zheng; Briseis A Kilfoy; Yawei Zhang
Journal:  Dose Response       Date:  2010-08-02       Impact factor: 2.658

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 3.  Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.

Authors:  Denise Skrombolas; John G Frelinger
Journal:  Expert Rev Clin Immunol       Date:  2014-02       Impact factor: 4.473

4.  Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.

Authors:  John Puskas; Denise Skrombolas; Abigail Sedlacek; Edith Lord; Mark Sullivan; John Frelinger
Journal:  Immunology       Date:  2011-03-23       Impact factor: 7.397

5.  A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model.

Authors:  Michael McLean; Howard L Wallace; Atima Sharma; Hank C Hill; Michael S Sabel; Nejat K Egilmez
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Authors:  Scott A Gerber; Elizabeth W Sorensen; Abigail L Sedlacek; Joanne Y H Lim; Denise Skrombolas; John G Frelinger; Edith M Lord
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

Review 7.  The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer.

Authors:  Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Clin Dev Immunol       Date:  2013-12-28

8.  Arsenic sulfide as a potential anti‑cancer drug.

Authors:  Wenping Ding; Lian Zhang; Sungkyoung Kim; Wei Tian; Yingying Tong; Jianwen Liu; Yong Ma; Siyu Chen
Journal:  Mol Med Rep       Date:  2014-11-03       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.